-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The SSE Science and Technology Innovation Board Biomedical Index (hereinafter referred to as the "Science and Technology Innovation Biomedical Index") refers to the selection of 50 securities of companies in the fields of biomedicine, biomedical engineering, and other biological industries with large market capitalization from the Science and Technology Innovation Board market as an ind.
A sample to reflect the overall performance of securities of listed companies in the biopharmaceutical industry that is representative of the STAR Mark.
Recently, the Shanghai Stock Exchange and China Securities Index .
, L.
officially released the Biomedical Index on the Science and Technology Innovation Board, and 50 biomedical companies with large market capitalization were includ.
According to statistics, 8 listed companies from Jiangsu are on the list, accounting for 1
The eight companies are Nanwei Medical, Nuotai Bio, Borui Pharmaceutical, Zejing Pharmaceutical, Shuo Shi Bio, Aidi Pharmaceutical, Weiss Medical, and Nano Micro Technolo.
Let's take a look at the situation of these 8 compani.
Nanwei Medical Nanwei Medical Company's main business is the inspection and minimally invasive surgical instruments used in conjunction with endoscopy, equipment and consumables required for microwave ablation, and was listed on the Science and Technology Innovation Board in July 201 At present, the market value of Nanwei Medical has reached 13 billion yu.
According to its 2021 annual report data, in 2021, the company's operating income will increase by 477% year-on-year to 947 billion yuan, and its net profit will increase by 254% year-on-year to 325 million yu.
In addition, in the first quarter of 2022, the company achieved revenue of about 443 million yuan; net profit of about 437 million yu.
Recently, Nanwei Medicine stated at the performance briefing that the company has relatively positive expectations for visualization products in 202 The main business of Nuotai Bio is the independent R&D and customized R&D and production of polypeptide drugs and small molecule chemical dru.
The terminal drugs served by the company cover AIDS, myelitis, tumors, diabetes, antiviral, cardiovascular diseases and other major diseas.
Disease treatment are.
According to the data, in 2021, Nuotai Bio will achieve an operating income of 644 million yuan, a year-on-year increase of 158%, and realize a net profit of 120 million yuan attributable to the pare.
Since the beginning of 2022, many institutions have continued to pay attention to and be optimistic about the company's developme.
The company has been rated as "buy" or "overweight" by Zhongtai Securities, Guoyuan Securities, Zheshang Securities and other institutio.
It is reported that at present, the company has formed a two-wheel drive strategic development system with customized R&D, production and technical service business (CDMO/CMO/CRO) as the main source of income, supplemented by independent product business income, with synergy and complementary advantages between businesses , to promote the steady growth of performan.
The company focuses its resources on the CDMO business field, and takes multiple measures to in-depth layout of this business module, showing a clear strategic development directi.
Borui Medicine Borui Medicine's main business is high-tech pharmaceuticals dedicated to the research, development and production of high-end generic drugs and original new dru.
The data shows that in the past 6 years, Borui Pharmaceutical has invested 670 million yuan in R&D, equivalent to 20% of its total revenue in the past 6 yea.
Relying on the long-acting PDC coupling technology platform, non-biological macromolecule technology platform, inhalation preparation platform and continuous R&D investment, Borui Medicine actively deploys the fields of tumor immunity and targeted therapy, iron preparations and respiratory inhalati.
Continued high R&D investment enables Borui Pharmaceuticals to focus on first imitation, difficult imitation, specialty APIs, high-end preparations and innovative dru.
At present, product sales revenue, including APIs and preparations, is still the company's main source of income and growth driv.
According to the data, in 2021, Borui Pharmaceutical's product sales revenue increased by 338% year-on-year to 928 million yu.
In addition to the API business, the revenue of preparation products in 2021 will increase by 308% year-on-year to 459 million yu.
Zejing Pharmaceutical Zejing Pharmaceutical's main business is the research and development of new chemical drugs and new biological dru.
According to the data, in 2021, Zejing Pharmaceutical achieved revenue of 190 million yuan, a year-on-year increase of 5819%, and research and development expenses of 510 million yuan, a year-on-year increase of 61
Continuing to increase R&D investment, Zejing Pharmaceutical has made many progre.
For example, in 2021, the Phase II clinical study including Jacktinib hydrochloride tablets in the treatment of intermediate and high-risk myelofibrosis will be successful, and the Phase III clinical trial will be launched; Test start,e.
In addition, Zejing Pharma has 42 major research projects of 16 major drug candidates, of which 8 indications of 4 drug candidates are in NDA, Phase III or registered clinical trials, and 5 drug candidates are in Phase I or clinical tria.
In the phase II clinical trial stage, 7 drug candidates are in the preclinical development sta.
Based on modern biological technology platforms such as multiplex fluorescence quantitative PCR and dry chemistry with independent intellectual property rights, the company has developed products covering infectious disease detection, tumor screening, women's Nearly 500 products in various fields such as reproductive tract microecological testing are widely used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, and prenatal and postnatal care management, realizing the integration of "instruments + reagents + services" business mod.
According to the data, in 2021, the total operating income of Shuoshi Bio will increase by 667% year-on-year to 86 billion yuan; the net profit attributable to owners of the parent company will increase by 410% year-on-year to 19 billion yu.
Aidi Pharmaceuticals Aidi Pharmaceuticals is a high-tech pharmaceutical company focusing on the pharmaceutical field, integrating drug research and development, production and sal.
The company has a core te.
Since its establishment, it has been deeply engaged in the field of human protein, focusing on major diseases that seriously threaten human health, and strives to build research and development pipelines in the fields of anti-AIDS, anti-inflammation and stro.
Demand-oriented, actively explore, develop and sell innovative dru.
The data shows that for the whole year of 2021, Aidi Pharmaceutical's R&D investment amounted to 76243 million yuan, a year-on-year increase of 676%; R&D investment accounted for 297% of operating income, an increase of 126 percentage points compared to the same period last ye.
In addition, the company's annual R&D investment capitalization rate was 49
Weiss Medical Weiss Medical's main business is to provide safe and effective rehabilitation products and overall solutions for medical and professional institutio.
It takes R&D and innovation as its development driving force and continues to invest in electrical stimulation, magnetic stimulation, electrophysiology, radio frequency, Advanced technology research and development in lasers, rehabilitation robots, e.
, and improve product layo.
The data shows that in 2021, Weiss Medical will achieve an operating income of 430 million yuan, a year-on-year increase of 166%, and a net profit of 178 million yuan, a year-on-year increase of 27
Among them, medical device income is 369 million yuan, an increase of 161% year-on-year, and other income is 56135 million yu.
, a year-on-year increase of 286%, and other business income was 3146 million yu.
Nano Micro Technology Nano Micro Technology is an enterprise engaged in the research and development and production of high-precision, high-performance and high-value-added microsphere materia.
It is also one of the companies that can simultaneously produce inorganic and organic high-performance nano-microsphere materials on a large sca.
On June 23, 2021, Nano Micro Technology was listed on the Science and Technology Innovation Board, and it rose more than ten times on the first day of listi.
By virtue of the "Dongfeng" selected in the Science and Technology Biomedical Index, Nano Micro Technology acquired 496% of the equity of Sepu Instruments, and is integrating the upstream and downstream product chains to expand into the field of instruments and equipme.
It is reported that Nano Micro Technology has the precise preparation technology, surface functionalization technology and large-scale production capacity of monodisperse chromatographic packing; products cover silica gel normal phase, reverse phase, HILIC, chiral packing, polymer reverse phase, ion exchange, hydrophobic layer Analysis, affinity chromatography (Protein A, metal chelation, phenylboronic acid), solid phase extraction, gel permeation chromatography and special functional fillers; also provide chromatographic columns, magnetic beads, standard particles, analysis and detection, separation and purification experimental skills training And the overall solution for separation and purificati.
Data shows that in the first quarter of 2022, Nano Micro Technology achieved operating income of 141 million yuan, a year-on-year increase of 117%; net profit attributable to the parent was 69236 million yuan, a year-on-year increase of 172
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
A sample to reflect the overall performance of securities of listed companies in the biopharmaceutical industry that is representative of the STAR Mark.
Recently, the Shanghai Stock Exchange and China Securities Index .
, L.
officially released the Biomedical Index on the Science and Technology Innovation Board, and 50 biomedical companies with large market capitalization were includ.
According to statistics, 8 listed companies from Jiangsu are on the list, accounting for 1
The eight companies are Nanwei Medical, Nuotai Bio, Borui Pharmaceutical, Zejing Pharmaceutical, Shuo Shi Bio, Aidi Pharmaceutical, Weiss Medical, and Nano Micro Technolo.
Let's take a look at the situation of these 8 compani.
Nanwei Medical Nanwei Medical Company's main business is the inspection and minimally invasive surgical instruments used in conjunction with endoscopy, equipment and consumables required for microwave ablation, and was listed on the Science and Technology Innovation Board in July 201 At present, the market value of Nanwei Medical has reached 13 billion yu.
According to its 2021 annual report data, in 2021, the company's operating income will increase by 477% year-on-year to 947 billion yuan, and its net profit will increase by 254% year-on-year to 325 million yu.
In addition, in the first quarter of 2022, the company achieved revenue of about 443 million yuan; net profit of about 437 million yu.
Recently, Nanwei Medicine stated at the performance briefing that the company has relatively positive expectations for visualization products in 202 The main business of Nuotai Bio is the independent R&D and customized R&D and production of polypeptide drugs and small molecule chemical dru.
The terminal drugs served by the company cover AIDS, myelitis, tumors, diabetes, antiviral, cardiovascular diseases and other major diseas.
Disease treatment are.
According to the data, in 2021, Nuotai Bio will achieve an operating income of 644 million yuan, a year-on-year increase of 158%, and realize a net profit of 120 million yuan attributable to the pare.
Since the beginning of 2022, many institutions have continued to pay attention to and be optimistic about the company's developme.
The company has been rated as "buy" or "overweight" by Zhongtai Securities, Guoyuan Securities, Zheshang Securities and other institutio.
It is reported that at present, the company has formed a two-wheel drive strategic development system with customized R&D, production and technical service business (CDMO/CMO/CRO) as the main source of income, supplemented by independent product business income, with synergy and complementary advantages between businesses , to promote the steady growth of performan.
The company focuses its resources on the CDMO business field, and takes multiple measures to in-depth layout of this business module, showing a clear strategic development directi.
Borui Medicine Borui Medicine's main business is high-tech pharmaceuticals dedicated to the research, development and production of high-end generic drugs and original new dru.
The data shows that in the past 6 years, Borui Pharmaceutical has invested 670 million yuan in R&D, equivalent to 20% of its total revenue in the past 6 yea.
Relying on the long-acting PDC coupling technology platform, non-biological macromolecule technology platform, inhalation preparation platform and continuous R&D investment, Borui Medicine actively deploys the fields of tumor immunity and targeted therapy, iron preparations and respiratory inhalati.
Continued high R&D investment enables Borui Pharmaceuticals to focus on first imitation, difficult imitation, specialty APIs, high-end preparations and innovative dru.
At present, product sales revenue, including APIs and preparations, is still the company's main source of income and growth driv.
According to the data, in 2021, Borui Pharmaceutical's product sales revenue increased by 338% year-on-year to 928 million yu.
In addition to the API business, the revenue of preparation products in 2021 will increase by 308% year-on-year to 459 million yu.
Zejing Pharmaceutical Zejing Pharmaceutical's main business is the research and development of new chemical drugs and new biological dru.
According to the data, in 2021, Zejing Pharmaceutical achieved revenue of 190 million yuan, a year-on-year increase of 5819%, and research and development expenses of 510 million yuan, a year-on-year increase of 61
Continuing to increase R&D investment, Zejing Pharmaceutical has made many progre.
For example, in 2021, the Phase II clinical study including Jacktinib hydrochloride tablets in the treatment of intermediate and high-risk myelofibrosis will be successful, and the Phase III clinical trial will be launched; Test start,e.
In addition, Zejing Pharma has 42 major research projects of 16 major drug candidates, of which 8 indications of 4 drug candidates are in NDA, Phase III or registered clinical trials, and 5 drug candidates are in Phase I or clinical tria.
In the phase II clinical trial stage, 7 drug candidates are in the preclinical development sta.
Based on modern biological technology platforms such as multiplex fluorescence quantitative PCR and dry chemistry with independent intellectual property rights, the company has developed products covering infectious disease detection, tumor screening, women's Nearly 500 products in various fields such as reproductive tract microecological testing are widely used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, and prenatal and postnatal care management, realizing the integration of "instruments + reagents + services" business mod.
According to the data, in 2021, the total operating income of Shuoshi Bio will increase by 667% year-on-year to 86 billion yuan; the net profit attributable to owners of the parent company will increase by 410% year-on-year to 19 billion yu.
Aidi Pharmaceuticals Aidi Pharmaceuticals is a high-tech pharmaceutical company focusing on the pharmaceutical field, integrating drug research and development, production and sal.
The company has a core te.
Since its establishment, it has been deeply engaged in the field of human protein, focusing on major diseases that seriously threaten human health, and strives to build research and development pipelines in the fields of anti-AIDS, anti-inflammation and stro.
Demand-oriented, actively explore, develop and sell innovative dru.
The data shows that for the whole year of 2021, Aidi Pharmaceutical's R&D investment amounted to 76243 million yuan, a year-on-year increase of 676%; R&D investment accounted for 297% of operating income, an increase of 126 percentage points compared to the same period last ye.
In addition, the company's annual R&D investment capitalization rate was 49
Weiss Medical Weiss Medical's main business is to provide safe and effective rehabilitation products and overall solutions for medical and professional institutio.
It takes R&D and innovation as its development driving force and continues to invest in electrical stimulation, magnetic stimulation, electrophysiology, radio frequency, Advanced technology research and development in lasers, rehabilitation robots, e.
, and improve product layo.
The data shows that in 2021, Weiss Medical will achieve an operating income of 430 million yuan, a year-on-year increase of 166%, and a net profit of 178 million yuan, a year-on-year increase of 27
Among them, medical device income is 369 million yuan, an increase of 161% year-on-year, and other income is 56135 million yu.
, a year-on-year increase of 286%, and other business income was 3146 million yu.
Nano Micro Technology Nano Micro Technology is an enterprise engaged in the research and development and production of high-precision, high-performance and high-value-added microsphere materia.
It is also one of the companies that can simultaneously produce inorganic and organic high-performance nano-microsphere materials on a large sca.
On June 23, 2021, Nano Micro Technology was listed on the Science and Technology Innovation Board, and it rose more than ten times on the first day of listi.
By virtue of the "Dongfeng" selected in the Science and Technology Biomedical Index, Nano Micro Technology acquired 496% of the equity of Sepu Instruments, and is integrating the upstream and downstream product chains to expand into the field of instruments and equipme.
It is reported that Nano Micro Technology has the precise preparation technology, surface functionalization technology and large-scale production capacity of monodisperse chromatographic packing; products cover silica gel normal phase, reverse phase, HILIC, chiral packing, polymer reverse phase, ion exchange, hydrophobic layer Analysis, affinity chromatography (Protein A, metal chelation, phenylboronic acid), solid phase extraction, gel permeation chromatography and special functional fillers; also provide chromatographic columns, magnetic beads, standard particles, analysis and detection, separation and purification experimental skills training And the overall solution for separation and purificati.
Data shows that in the first quarter of 2022, Nano Micro Technology achieved operating income of 141 million yuan, a year-on-year increase of 117%; net profit attributable to the parent was 69236 million yuan, a year-on-year increase of 172
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
